The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome

Hepatology

Volumn 62, Issue 3, 2015, Pages 956-963

  Marzano, Chiara ^a   Cazals Hatem, Dominique ^b,c   Rautou, Pierre Emmanuel ^b,d   Valla, Dominique Charles ^b,c,e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BEAUJON HOSPITAL   (France)

^c CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^d INSERM   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; INTERLEUKIN 6; NOTCH1 RECEPTOR; ORAL CONTRACEPTIVE AGENT; OXALIPLATIN; STEROID; VASCULOTROPIN; OXIPLATIN; PLATINUM COMPLEX; PYRIDINE DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; HUMAN; INFECTION; INFLAMMATION; INFLAMMATORY REACTION SYNDROME; LIVER HISTOLOGY; LIVER PERFUSION; LIVER SINUSOID; NEOPLASM; NONHUMAN; PATHOGENESIS; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; REVIEW; SINUSOIDAL DILATION; VASCULAR DISEASE; ANIMAL; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; LIVER CIRCULATION; MALE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN; PROGNOSIS; RISK ASSESSMENT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; HYPERTENSION, PORTAL; INTERLEUKIN-6; LIVER CIRCULATION; MALE; MICE; ORGANOPLATINUM COMPOUNDS; PORTAL SYSTEM; PROGNOSIS; PYRIDINES; RISK ASSESSMENT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939652584     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27747     Document Type: Review

References (88)

1. Saadoun D, Cazals-Hatem D, Denninger MH, Boudaoud L, Pham BN, Mallet V, et al. Association of idiopathic hepatic sinusoidal dilatation with the immunological features of the antiphospholipid syndrome. Gut 2004;53:1516-1519.
2. Kakar S, Kamath PS, Burgart LJ. Sinusoidal dilatation and congestion in liver biopsy: is it always due to venous outflow impairment? Arch Pathol Lab Med 2004;128:901-904.
3. Poulsen H, Winkler K, Christoffersen P. The significance of centrilobular sinusoidal changes in liver biopsies. Scand J Gastroenterol Suppl 1970;7:103-109.
4. Bruguera M, Aranguibel F, Ros E, Rodes J. Incidence and clinical significance of sinusoidal dilatation in liver biopsies. Gastroenterology 1978;75:474-478.
5. Wisse E, De Zanger RB, Charels K, Van Der Smissen P, McCuskey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 1985;5:683-692.
6. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009;49:1729-1764.
7. Zafrani ES, Cazier A, Baudelot AM, Feldmann G. Ultrastructural lesions of the liver in human peliosis. A report of 12 cases. Am J Pathol 1984;114:349-359.
8. Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver. Hepatology 1997;26:343-350.
9. Verheij J, Schouten JN, Komuta M, Nevens F, Hansen BE, Janssen HL, et al. Histological features in Western patients with idiopathic non-cirrhotic portal hypertension. Histopathology 2013;62:1083-1091.
10. Harada H, Imamura H, Miyagawa S, Kawasaki S. Fate of the human liver after hemihepatic portal vein embolization: cell kinetic and morphometric study. Hepatology 1997;26:1162-1170.
11. Agnihotri N, Bhusnurmath SR, Narasimhan KL, Dilawari JB, Majumdar S, Kaur U. Experimental extrahepatic obstruction of portal vein: documentation of histopathological alterations in liver and extrahepatic tissues. J Gastroenterol Hepatol 1996;11:971-977.
12. Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol 2011;54:455-461.
13. Tsuneyama K, Ohba K, Zen Y, Sato Y, Niwa H, Minato H, et al. A comparative histological and morphometric study of vascular changes in idiopathic portal hypertension and alcoholic fibrosis/cirrhosis. Histopathology 2003;43:55-61.
14. Witters P, Maleux G, George C, Delcroix M, Hoffman I, Gewillig M, et al. Congenital veno-venous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol 2008;23:e390-e394.
15. Taieb J, Castera L, Boige V, Frouge C, Bedossa P, Bernard O, et al. Hepatocellular carcinoma complicating agenesis of the portal vein. [in French] Gastroenterol Clin Biol 1998;22:246-247.
16. Bioulac-Sage P, Saric J, Boussarie L, Balabaud C. Congenital portacaval shunt in rats: liver adaptation to lack of portal vein-a light and electron microscopic study. Hepatology 1985;5:1183-1189.
17. Aoyagi T, Mori I, Ueyama Y, Tamaoki N. Sinusoidal dilatation of the liver as a paraneoplastic manifestation of renal cell carcinoma. Hum Pathol 1989;20:1193-1197.
18. Delpre G, Ilie B, Papo J, Streifler C, Gefel A. Hypernephroma with nonmetastatic liver dysfunction (Stauffer's syndrome) and hypercalcemia. Case report and review of the literature. Am J Gastroenterol 1979;72:239-247.
19. Bruguera M, Caballero T, Carreras E, Aymerich M, Rodes J, Rozman C. Hepatic sinusoidal dilatation in Hodgkin's disease. Liver 1987;7:76-80.
20. Paradis V, Champault A, Ronot M, Deschamps L, Valla DC, Vidaud D, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007;46:140-146.
21. Bioulac-Sage P, Laumonier H, Cubel G, Rossi JZ, Balabaud C. Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins. Liver Int 2010;30:149-154.
22. Han J, van den Heuvel MC, Kusano H, de Jong KP, Gouw AS. How normal is the liver in which the inflammatory type hepatocellular adenoma develops? Int J Hepatol 2012;2012:805621.
23. Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist 2011;16:1316-1324.
24. Curciarello J, Castelletto R, Barbero R, Belloni P, Gelemur M, Castelletto E, et al. Hepatic sinusoidal dilatation associated to giant lymph node hyperplasia (Castleman's): a new case in a patient with periorbital xanthelasmas and history of celiac disease. J Clin Gastroenterol 1998;27:76-78.
25. De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, et al. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol 2008;43:604-608.
26. Capron JP, Lemay JL, Gontier MF, Dupas JL, Capron-Chivrac D, Lorriaux A. Hepatic sinusoidal dilatation in Crohn's disease. Scand J Gastroenterol 1979;14:987-992.
27. Camilleri M, Schafler K, Chadwick VS, Hodgson HJ, Weinbren K. Periportal sinusoidal dilatation, inflammatory bowel disease, and the contraceptive pill. Gastroenterology 1981;80:810-815.
28. Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007;56:1404-1409.
29. Laffon A, Moreno A, Gutierrez-Bucero A, Ossorio C, Sabando P, Moreno-Otero R. Hepatic sinusoidal dilatation in rheumatoid arthritis. J Clin Gastroenterol 1989;11:653-657.
30. Qizilbash AH, Castelli M. Nodular regenerative hyperplasia of the liver: diagnosis by liver biopsy. Can Med Assoc J 1980;122:1151-1154.
31. Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver 2000;20:366-373.
32. Akritidis N, Tzivras M, Delladetsima I, Stefanaki S, Moutsopoulos HM, Pappas G. The liver in brucellosis. Clin Gastroenterol Hepatol 2007;5:1109-1112.
33. Meyniel D, Touboul JL, Pieron R, Chatelet F. Hepatic tuberculosis: anatomical and clinical findings. A review of forty-six cases. [in French] Sem Hop 1982;58:1023-1026.
34. Gendron Y, Peghini M. Liver needle biopsy in evolutive tuberculosis of adult Africans. Report on 142 cases. [in French] Med Trop (Mars) 1982;42:43-46.
35. Kent G, Thompson JR. Peliosis hepatis: involvement of reticuloendothelial system. Arch Pathol 1961;72:658-664.
36. Garnier T, Parelon G, Bauret P, Ampelas M, Bories P, Michel H. Peliosis hepatis associated with pulmonary tuberculosis simulating acute alcoholic hepatitis. [in French] Gastroenterol Clin Biol 1986;10:774-775.
37. Bach N, Theise ND, Schaffner F. Hepatic histopathology in the acquired immunodeficiency syndrome. Semin Liver Dis 1992;12:205-212.
38. Reed JA, Brigati DJ, Flynn SD, McNutt NS, Min KW, Welch DF, et al. Immunocytochemical identification of Rochalimaea henselae in bacillary (epithelioid) angiomatosis, parenchymal bacillary peliosis, and persistent fever with bacteremia. Am J Surg Pathol 1992;16:650-657.
39. Mohle-Boetani JC, Koehler JE, Berger TG, LeBoit PE, Kemper CA, Reingold AL, et al. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: clinical characteristics in a case-control study. Clin Infect Dis 1996;22:794-800.
40. Perkocha LA, Geaghan SM, Yen TS, Nishimura SL, Chan SP, Garcia-Kennedy R, et al. Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection. N Engl J Med 1990;323:1581-1586.
41. Sommacale D, Palladino E, Tamby EL, Diebold MD, Kianmanesh AR. Spontaneous hepatic rupture in a patient with peliosis hepatis: a report of one case. Int J Surg Case Rep 2013;4:508-510.
42. Winkler K, Poulsen H. Liver disease with periportal sinusoidal dilatation. A possible complication to contraceptive steroids. Scand J Gastroenterol 1975;10:699-704.
43. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-1982. Tender hepatomegaly in a 29-year-old woman. N Engl J Med 1982;307:934-942.
44. Weinberger M, Garty M, Cohen M, Russo Y, Rosenfeld JB. Ultrasonography in the diagnosis and follow-up of hepatic sinusoidal dilatation. Arch Intern Med 1985;145:927-929.
45. Fischer D, Kemeny F, Rauturseau J, Marty M, Karsenti P. Massive, painful hepatomegaly, sinusoidal dilatation and prolonged use of estroprogestational agents. [in French] Gastroenterol Clin Biol 1982;6:302-304.
46. Molleken K, Stahl E, Bretzke G. Morphological and clinical liver changes after taking oral contraceptives. [in German] Z Gesamte Inn Med 1979;34:79-81.
47. Spellberg MA, Mirro J, Chowdhury L. Hepatic sinusoidal dilatation related to oral contraceptives. A study of two patients showing ultrastructural changes. Am J Gastroenterol 1979;72:248-252.
48. Bretagne J, Deugnier Y, Gosselin M, Gastard J. Hepatomégalie douloureuse et fièvre après prise d'oestroprogestatifs. Sem Hop Paris 1984;60:3231:3232.
49. Fisher MR, Neiman HL. Periportal sinusoidal dilatation associated with pregnancy. Cardiovasc Intervent Radiol 1984;7:299-302.
50. Paradinas FJ, Bull TB, Westaby D, Murray-Lyon IM. Hyperplasia and prolapse of hepatocytes into hepatic veins during longterm methyltestosterone therapy: possible relationships of these changes to the developement of peliosis hepatis and liver tumours. Histopathology 1977;1:225-246.
51. Tsirigotis P, Sella T, Shapira MY, Bitan M, Bloom A, Kiselgoff D, et al. Peliosis hepatis following treatment with androgen-steroids in patients with bone marrow failure syndromes. Haematologica 2007;92:e106-e110.
52. Cabasso A. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc 1994;26:2-4.
53. Seksik P, Mary JY, Beaugerie L, Lemann M, Colombel JF, Vernier-Massouille G, et al. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis 2011;17:565-572.
54. Degos F, Degott C, Bedrossian J, Camilieri JP, Barbanel C, Duboust A, et al. Is renal transplantation involved in post-transplantation liver disease? A prospective study. Transplantation 1980;29:100-102.
55. Rao KV, Anderson WR, Kasiske BL, Dahl DC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993;94:241-250.
56. Larrey D, Freneaux E, Berson A, Babany G, Degott C, Valla D, et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988;29:1265-1269.
57. Jacobi AM, Feist E, Rudolph B, Burmester GR. Sinusoidal dilatation: a rare side effect of azathioprine. Ann Rheum Dis 2004;63:1702-1703.
58. Russmann S, Zimmermann A, Krahenbuhl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001;13:287-290.
59. Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005;43:303-309.
60. Izumi S, Nishiuchi M, Kameda Y, Nagano S, Fukunishi T, Kohro T, et al. Laparoscopic study of peliosis hepatis and nodular transformation of the liver before and after renal transplantation: natural history and aetiology in follow-up cases. J Hepatol 1994;20:129-137.
61. de Fontbrune FS, Mal H, Dauriat G, Brugiere O, Biondi G, Taille C, et al. Veno-occlusive disease of the liver after lung transplantation. Am J Transplant 2007;7:2208-2211.
62. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010;56:430-439.
63. Nguyen-Khac E, Lobry C, Chatelain D, Fuks D, Joly JP, Brevet M, et al. A reappraisal of chemotherapy-induced liver injury in colorectal liver metastases before the era of antiangiogenics. Int J Hepatol 2013;2013:314868.
64. Maione D, Di Carlo E, Li W, Musiani P, Modesti A, Peters M, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J 1998;17:5588-5597.
65. Schirmacher P, Peters M, Ciliberto G, Blessing M, Lotz J, Meyer zum Buschenfelde KH, et al. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol 1998;153:639-648.
66. Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997;72:424-430.
67. Gaiolla RD, Domingues MA, Niero-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med 2011;135:483-489.
68. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-2632.
69. Nancey S, Hamzaoui N, Moussata D, Graber I, Bienvenu J, Flourie B. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci 2008;53:242-247.
70. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2011;90:484-494.
71. Havlir DV, Torriani FJ, Schrier RD, Huang JY, Lederman MM, Chervenak KA, et al. Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol 2001;39:298-303.
72. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013;144:888-902.
73. Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD. Portal branch ligation induces a hepatic arterial buffer response, microvascular remodeling, normoxygenation, and cell proliferation in portal blood-deprived liver tissue. Am J Physiol Gastrointest Liver Physiol 2007;292:G1534-G1542.
74. Kobayashi S, Nagino M, Yokoyama Y, Nimura Y, Sokabe M. Evaluation of hepatic interleukin-6 secretion following portal vein ligation using a minimal surgical stress model. J Surg Res 2006;135:27-33.
75. Koksal AS, Koklu S, Ibis M, Balci M, Cicek B, Sasmaz N, et al. Clinical features, serum interleukin-6, and interferon-gamma levels of 34 Turkish patients with hepatoportal sclerosis. Dig Dis Sci 2007;52:3493-3498.
76. Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol 2013;59:318-326.
77. Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, et al. Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther 2011;10:687-696.
78. Croquelois A, Blindenbacher A, Terracciano L, Wang X, Langer I, Radtke F, et al. Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 2005;41:487-496.
79. Dill MT, Rothweiler S, Djonov V, Hlushchuk R, Tornillo L, Terracciano L, et al. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology 2012;142:967-977.
80. Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD, et al. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci USA 2001;98:7481-7486.
81. Niers TM, Richel DJ, Meijers JC, Schlingemann RO. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One 2011;6:e19873.
82. Berrich M, Kieda C, Grillon C, Monteil M, Lamerant N, Gavard J, et al. Differential effects of Bartonella henselae on human and feline macro- and micro-vascular endothelial cells. PLoS One 2011;6:e20204.
83. Agostini J, Benoist S, Seman M, Julie C, Imbeaud S, Letourneur F, et al. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. J Hepatol 2012;56:869-876.
84. van der Pool AE, Marsman HA, Verheij J, Ten Kate FJ, Eggermont AM, Ijzermans JN, et al. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol 2012;106:892-897.
85. Raufman JP, Miller DL, Gumucio JJ. Estrogen-induced zonal changes in rat liver sinusoids. Gastroenterology 1980;79:1174-1177.
86. Karbalay-Doust S, Noorafshan A. Stereological study of the effects of nandrolone decanoate on the mouse liver. Micron 2009;40:471-475.
87. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996;23:589-599.
88. Kojda G, Hambrecht R. Molecular mechanisms of vascular adaptations to exercise. Physical activity as an effective antioxidant therapy? Cardiovasc Res 2005;67:187-197.